Quantcast

OHK Medical Devices to Exhibit at 2013 AAOS Annual Meeting (Booth 1108) on March 20-22, 2013 in Chicago

March 6, 2013

OHK Medical Devices Ltd., manufacturer of the HemaClear® single-use, sterile, exsanguinating tourniquet device, announced today that it will be exhibiting at the 2013 AAOS Annual Meeting — Booth 1108 — March 20-22, 2013 in Chicago.

Chicago, IL (PRWEB) March 06, 2013

OHK Medical Devices Ltd., manufacturer of the HemaClear® single-use, sterile exsanguinating tourniquet device, announced today that it will be exhibiting at the 2013 AAOS Annual Meeting. The meeting will take place March 20th through the 22nd in Chicago. The company is excited to celebrate major clinical milestones and increase the presence of the growing tourniquet of choice.

In 2012, OHK Medical Devices celebrated the 500,000 application of HemaClear®. Further, it celebrated the successful launch of HemaClear® in multiple countries including Australia, France, and South Korea..

“We are very excited to showcase our tourniquet technology. The meeting provides a unique opportunity to introduce surgeons to the first innovation in the field in over a century,” said Omer Inbar, VP of Sales, OHK Medical Devices. Mr. Inbar added that, “After a very strong year in 2012, we are off to a fantastic start in 2013 as HemaClear sales continue to take off; Our current expansion efforts combine creating a presence in new markets such as Latin America, Eastern Europe and Scandinavia and deepening our footprint in the existing markets in Europe and the US.”

OHK Medical Devices will be exhibiting in Hall A at the McCormick Place, booth #1108. Surgeons and industry professionals are urged to come by the booth and learn why HemaClear® is quickly becoming the global tourniquet of choice.

About HemaClear®

HemaClear® is the world´s leading sterile tourniquet with a simple yet innovative technology, representing a new standard of care in bloodless orthopedic surgery. Since entering the market in 2007 this product has been successfully used in almost 500,000 procedures. Easier, cheaper and safer than the standard offerings, HemaClear® represents the first significant advancement in tourniquet technology in over 100 years. HemaClear® was developed by OHK Medical Devices (OHK), a privately held company based in Haifa, Israel and the United States and is currently used in over 2000 operating rooms across 30 countries. For more information about HemaClear®, visit http://www.hemaclear.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/3/prweb10498272.htm


Source: prweb



comments powered by Disqus